Early Commercial Lead - Fibrostenosing Crohn’s Disease

Job description

Early Commercial Lead - Fibrostenosing Crohn’s Disease Department: Business Development: Employment Type: Full Time: Location: Agomab Antwerp: Description: We are looking for an Early Commercial Lead to shape the commercial strategy for Ontunisertib, a GI-restricted small molecule ALK5 inhibitor currently ready for Phase 2b development in Fibrostenosing Crohn’s Disease (FSCD). FSCD represents a significant unmet need within the Crohn’s disease population, with limited therapeutic options addressing the intestinal fibrosis and stricturing complications. Ontunisertib is the most advanced clinical candidate for the potential treatment of FSCD. The role will play a pivotal part in defining the future value proposition, positioning, and evidence strategy for Ontunisertib as it progresses through clinical development. As the commercial lead for Ontunisertib, you will work closely with clinical development, regulatory and corporate functions to ensure that future development plans align with the market. The role sits at the intersection of science, clinical strategy, corporate and commercial planning, helping translate emerging clinical insights into a compelling strategy that ultimately...